Captain Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship with Trough FEV1

被引：0
|
作者：
Fowler, A. [1 ]
Kerstjens, H. [2 ,3 ]
Bailes, Z. [1 ]
Tabberer, M. [1 ]
Barnes, N. [4 ,5 ,6 ,7 ]
Peachey, G. [1 ]
Oppenheimer, J. [8 ]
Lee, L. [9 ]
机构：
[1] GSK, Stockley Pk West, Uxbridge, Middx, England
[2] Univ Groningen, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] GSK, Brentford, England
[5] Barts & London Queen Marys Sch Med & Dent, Brentford, England
[6] GSK, London, England
[7] Barts & London Queen Marys Sch Med & Dent, London, England
[8] Rutgers New Jersey Med Sch, Newark, NJ USA
[9] GSK, Collegeville, PA USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5626
引用
收藏
页数：2
相关论文
共 22 条
  • [11] Unveiling the Clinical Profiles for Patients With Asthma and Chronic Obstructive Pulmonary Disease Starting Single-inhaler Triple Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/ UMEC/VI)
    Narendra, D.
    Baptist, A. P.
    Lee, L.
    Noorduyn, S. G.
    Liu, M.
    Igboekwe, E. E.
    Veeranki, P.
    Kahle-Wrobleski, K.
    Paczkowski, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [12] Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial (vol 9, pg 69, 2021)
    Lee, L. A.
    Bailes, Z.
    Barnes, N.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (02): : E18 - E18
  • [13] Captain Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, A Pre-Specified Subgroup Analysis
    Pavord, I. D.
    Fowler, A.
    Kerstjens, H.
    Papi, A.
    Hartley, B.
    Goldfrad, C.
    Barnes, N.
    Oppenheimer, J.
    Pizzichini, E.
    Lee, L. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [14] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [15] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 24
  • [16] Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
    Afisi S. Ismaila
    Kieran J. Rothnie
    Robert P. Wood
    Victoria L. Banks
    Lucinda J. Camidge
    Alexandrosz Czira
    Chris Compton
    Raj Sharma
    Shannon N. Millard
    Olivia Massey
    David M. G. Halpin
    Respiratory Research, 25
  • [17] Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study (vol 24, 229, 2023)
    Ismaila, Afisi S.
    Rothnie, Kieran J.
    Wood, Robert P.
    Banks, Victoria L.
    Camidge, Lucinda J.
    Czira, Alexandrosz
    Compton, Chris
    Sharma, Raj
    Millard, Shannon N.
    Massey, Olivia
    Halpin, David M. G.
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [18] The efficacy and safety of Fluticasone Furoate/Umeclidinium/vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, a randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study
    Tagaya, Etsuko
    Shinada, Jun
    Nagase, Hiroyuki
    Terada-Hirashima, Junko
    Hojo, Masayuki
    Sugihara, Naruhiko
    Yagi, Osamitsu
    Tsuji, Mayoko
    Akaba, Tomohiro
    Masaki, Katsunori
    Fukunaga, Koichi
    Ohbayashi, Hiroyuki
    Chiba, Kaoru
    Hozawa, Soichiro
    Atsuta, Ryo
    Aoki, Yasuhiro
    Hiranuma, Hisato
    Gon, Yasuhiro
    Tanaka, Akihiko
    JOURNAL OF ASTHMA, 2025,
  • [19] Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study
    Hozawa, Soichiro
    Ohbayashi, Hiroyuki
    Tsuchiya, Michiko
    Hara, Yu
    Lee, Laurie A.
    Nakayama, Takashi
    Tamaoki, Jun
    Fowler, Andrew
    Nishi, Takanobu
    JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 809 - 819
  • [20] Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial
    Devillier, Philippe
    Humbert, Marc
    Boye, Alain
    Zachgo, Wolfgang
    Jacques, Loretta
    Nunn, Carol
    West, Sarah
    Nicholls, Andy
    Antoun, Zeina
    Spinu, Luminita
    Grouin, Jean-Marie
    RESPIRATORY MEDICINE, 2018, 141 : 111 - 120
123